Home > Insider Trading > Filing (0001179110-21-001370)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1730430	Kiniksa Pharmaceuticals Ltd.	KNSA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1741382	W. Thomas Beetham	C/O Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton D0 HM11	Evp & Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Shares	Acquisiton	2021-02-03	300,000	$0.00	300,000	No	4	C	Direct
Class A Common Shares	Disposition	2021-02-03	2,477	$22.09	297,523	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Shares	Class B Common Shares	Disposition	2021-02-03	300,000	$0.00	300,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
114,157			No	4	C	Direct

Footnotes

Each Class B Common Share is convertible at any time at the election of the holder into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.
The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on June 19, 2020.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $22.05 to $22.18. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.